跳至主要内容
临床试验/EUCTR2011-000903-41-BE
EUCTR2011-000903-41-BE进行中(未招募)1 期

AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATAFROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB(CP-690,550) IN COMPLETED PHASE 2 STUDIES

Pfizer Inc.235 East 42nd Street, New York, NY 100170 个研究点目标入组 110 人开始时间: 2011年9月1日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subjects must meet all of the following criteria to be eligible for enrollment into the trial:
  • 1. Subject must meet at least 1 of the following 2 criteria:
  • a. Subjects have discontinued tofacitinib prior to the planned treatment duration of study A3921009 (6 months posttransplant) or study A3921030 (12 months posttransplant); or
  • b. Subjects have not enrolled in the extension studies A3921021 or A3921050.
  • 2. Subjects must be willing and able to provide written informed consent with evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all the pertinent
  • aspects of the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 94
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 16

排除标准

  • Not applicable

研究者

发起方
Pfizer Inc.235 East 42nd Street, New York, NY 10017

相似试验